BEAM
Income statement / Annual
Last year (2023), Beam Therapeutics Inc.'s total revenue was $377.71 M,
an increase of 520.01% from the previous year.
In 2023, Beam Therapeutics Inc.'s net income was -$132.53 M.
See Beam Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$377.71 M
|
$60.92 M
|
$51.84 M
|
$24,000.00
|
$18,000.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$437.38 M |
$22.58 M |
$16.44 M |
$103.18 M |
$5.41 M |
$650,000.00 |
$11,000.00 |
| Gross Profit |
-$59.67 M |
$38.34 M |
$35.40 M |
-$103.16 M |
-$5.39 M |
-$650,000.00 |
-$11,000.00 |
| Gross Profit Ratio |
-0.16 |
0.63 |
0.68 |
-4298.13 |
-299.39 |
0 |
0 |
| Research and Development
Expenses |
$437.38 M
|
$311.59 M
|
$387.09 M
|
$103.18 M
|
$54.62 M
|
$33.87 M
|
$5.86 M
|
| General & Administrative
Expenses |
$116.81 M
|
$87.81 M
|
$57.22 M
|
$29.61 M
|
$20.55 M
|
$11.87 M
|
$2.02 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$116.81 M
|
$87.81 M
|
$57.22 M
|
$29.61 M
|
$20.55 M
|
$11.87 M
|
$2.02 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$71,000.00 |
-$10.04 M |
$378,000.00 |
| Operating Expenses |
$554.19 M |
$399.40 M |
$444.31 M |
$132.78 M |
$75.17 M |
$45.74 M |
$7.88 M |
| Cost And Expenses |
$554.19 M |
$399.40 M |
$444.31 M |
$132.78 M |
$75.17 M |
$45.74 M |
$7.88 M |
| Interest Income |
$0.00 |
$15.30 M |
$9,000.00 |
$1.57 M |
$2.49 M |
$292,000.00 |
$0.00 |
| Interest Expense |
$0.00 |
$15.30 M |
$9,000.00 |
$1.57 M |
$187,000.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$20.01 M
|
$22.58 M
|
$16.44 M
|
$9.47 M
|
$5.41 M
|
$650,000.00
|
$11,000.00
|
| EBITDA |
-$156.47 M
|
-$324.33 M
|
-$392.47 M
|
-$128.03 M
|
-$71.65 M
|
-$45.09 M
|
-$7.99 M
|
| EBITDA Ratio |
-0.41 |
-6.59 |
-7.99 |
-2692.71 |
-3846.44 |
0 |
0 |
| Operating Income Ratio
|
-0.47
|
-5.56
|
-7.57
|
-5531.67
|
-4175.22
|
0
|
0
|
| Total Other
Income/Expenses Net |
$45.32 M
|
$78.30 M
|
$21.83 M
|
-$61.83 M
|
-$3.17 M
|
-$71.00 M
|
-$122,000.00
|
| Income Before Tax |
-$131.16 M |
-$260.18 M |
-$370.64 M |
-$194.59 M |
-$78.33 M |
-$116.74 M |
-$8.00 M |
| Income Before Tax Ratio
|
-0.35
|
-4.27
|
-7.15
|
-8108
|
-4351.44
|
0
|
0
|
| Income Tax Expense |
$1.37 M |
$3.41 M |
-$29.28 M |
$61.83 M |
$116,000.00 |
-$71.00 M |
$500,000.00 |
| Net Income |
-$132.53 M |
-$263.59 M |
-$341.36 M |
-$256.42 M |
-$78.44 M |
-$115.26 M |
-$8.00 M |
| Net Income Ratio |
-0.35 |
-4.33 |
-6.58 |
-10684.33 |
-4357.89 |
0 |
0 |
| EPS |
-1.72 |
-3.76 |
-5.31 |
-5.49 |
-1.53 |
-3.28 |
-0.62 |
| EPS Diluted |
-1.72 |
-3.76 |
-5.31 |
-5.49 |
-1.53 |
-3.28 |
-0.62 |
| Weighted Average Shares
Out |
$77.15 M
|
$70.02 M
|
$64.23 M
|
$46.73 M
|
$51.34 M
|
$35.14 M
|
$12.95 M
|
| Weighted Average Shares
Out Diluted |
$77.15 M
|
$70.02 M
|
$64.23 M
|
$46.73 M
|
$51.34 M
|
$35.14 M
|
$12.95 M
|
| Link |
|
|
|
|
|
|
|
